Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 19/20 | 0.53 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.48 |
| ▸ | AKT3 | Q9Y243 | 3/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.42 |
| ▸ | PIM1 | P11309 | 2/20 | 0.42 |
| ▸ | AKT2 | P31751 | 2/20 | 0.42 |
| ▸ | GSK3A | P49840 | 2/20 | 0.42 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.42 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.42 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.42 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.42 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.42 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | CDC7 | O00311 | 1/20 | 0.40 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.40 |
| ▸ | CHUK | O15111 | 1/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4659492 | 1.00 | AKT1 (0.53) | AKT1ROCK1AKT3ROCK2PIM1 | |
| SCHEMBL4658741 | 0.91 | AKT1 (0.52) | AKT1ROCK1AKT3ROCK2PIM1 | |
| SCHEMBL4658737 | 0.91 | AKT1 (0.52) | AKT1ROCK1AKT3ROCK2PIM1 | |
| SCHEMBL4659494 | 0.83 | AKT1 (0.55) | AKT1ROCK1AKT3AKT2GSK3B | |
| SCHEMBL4660690 | 0.81 | AKT1 (0.62) | AKT1ROCK1AKT3AKT2GSK3B | |
| SCHEMBL6854709 | 0.80 | AKT1 (0.80) | AKT1ROCK1AKT3ROCK2PIM1 | |
| SCHEMBL4659785 | 0.78 | AKT1 (0.63) | AKT1ROCK1AKT3ROCK2PIM1 | |
| SCHEMBL4659784 | 0.78 | AKT1 (0.63) | AKT1ROCK1AKT3ROCK2PIM1 | |
| SCHEMBL4658594 | 0.77 | AKT1 (0.79) | AKT1ROCK1AKT3ROCK2PIM1 | |
| SCHEMBL4658589 | 0.77 | AKT1 (0.79) | AKT1ROCK1AKT3ROCK2PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720855-A4 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORP (US) | 2008-12-17 | — | — | EP | claimed |
| US-20070185152-A1 | Inhibitors of akt activity | SMITHKLINE BEECHAM CORPORATION | 2007-08-09 | — | — | US | claimed |
| EP-1720855-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-15 | — | — | EP | claimed |
| WO-2005085227-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-15 | — | — | WO | claimed |
| EP-1720855-A4 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORP (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20070185152-A1 | Inhibitors of akt activity | SMITHKLINE BEECHAM CORPORATION | 2007-08-09 | — | — | US | disclosed |
| EP-1720855-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005085227-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185152-A1 | Inhibitors of akt activity | AKT1, AKT1S1, AKT2 | AKT1 1/4885ROCK1 589/4885AKT3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.